Puma Biotechnology Sees Q2 Net Product Revenue $43M-$45M; FY24 Net Product Revenue $183M-$190M
Portfolio Pulse from Benzinga Newsdesk
Puma Biotechnology projects Q2 net product revenue to be between $43M-$45M and forecasts full-year 2024 revenue to range from $183M-$190M. The company also anticipates royalty revenue and license revenue, alongside a net income of $12M-$15M for FY24.
May 02, 2024 | 9:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Puma Biotechnology forecasts an increase in net product revenue for Q2 and FY24, alongside positive net income for FY24.
The projected increase in net product revenue and the anticipation of positive net income for FY24 suggest a strong financial outlook for Puma Biotechnology. This positive financial guidance is likely to instill investor confidence, potentially leading to an uptick in PBYI's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100